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Ki-67 expression in soft tissue sarcomas in children
Bernarda Kazanowska1, Adam Reich2, Micha∏ Jeleƒ3,
Teresa Szkudlarek3, Alicja Chybicka1
I n t r o d u c t i o n.  Expression of the Ki-67 antigen is one of the markers of cell proliferation. The proliferation index has been
successfully used as a prognostic marker in many malignant tumours. The aim of this study was to establish the prognostic
relevance of Ki-67 antigen expression in soft tissue sarcomas in children and to compare Ki-67 expression with some selected
clinical parameters.
M a t e r i a l  a n d  m e t h o d s.  113 children (65 boys and 48 girls) aged between 1 and 217 months with diagnosed soft tissue
sarcomas entered the study. Four patients were at stage I, 12 at stage II, 63 at stage III, and 34 patients, at the time of
diagnosis, presented distant metastases. The activity of Ki-67 antigen was evaluated in paraffin-embedded tissue samples of
tumours using the DAKO kit. The examination of Ki-67 expression was performed on Olympus BX 50 microscope connected
to PC computer (equipped with Pentium 130 MHz and graphic card: Frame Grabber) and graphic MultiScan 5.10 software,
Computer Scanning System. The Ki-67 expression was assessed in 500 cell of each case in several randomly chosen visual fields
and the percentage of Ki-67 positive cells was calculated.
Re s u l t s.  The mean proliferation index in the analysed group was 18.5%. The highest average of Ki-67 expression was noted
in alveolar rhabdomyosarcoma. The high activity of the Ki-67 antigen was associated with a poorer response to induction
chemotherapy (p<0.05), and with shorter event free survival (5-years EFS: 0.44 and 0.26; p<0.05) and overall survival (5-
years OS: 0.55 and 0.31; p=0.03). Moreover, patients with high Ki-67 expression had a smaller chance to survive after
relapse (p=0.011). However, no significant difference was observed between Ki-67 activity and tumour size and stage, stage
of disease, infiltration of regional lymph nodes and presence of distant metastases.
C o n c l u s i o n.  We conclude, that Ki-67 antigen expression is a significant prognostic marker in soft tissue sarcomas in
children and that the evaluation of this parameter could be helpful in precise pre-treatment stratification and may thus
optimize the efficacy of the therapeutic modalities.
Ekspresja antygenu Ki-67 w mi´sakach tkanek mi´kkich u dzieci
W s t ´ p.  Ekspresja antygenu Ki-67 jest uznawana za jeden z markerów aktywnoÊci proliferacyjnej komórek. Indeks
proliferacyjny okaza∏ si´ skutecznym czynnikiem rokowniczym w wielu nowotworach. Celem obecnej pracy by∏o zbadanie
ekspresji antygenu Ki-67 w komórkach mi´saków tkanek mi´kkich u dzieci i ocena wp∏ywu tego parametru na prze˝ycie
pacjentów, a tak˝e porównanie ekspresji antygenu Ki-67 z wybranymi parametrami klinicznymi.
M a t e r i a ∏  i m e t o d a.  Badaniem obj´to 113 dzieci (65 ch∏opców i 48 dziewczynek) w wieku od 1 do 217 miesi´cy
z rozpoznanym mi´sakiem tkanek mi´kkich. Po pierwotnym zabiegu chirurgicznym w I stadium klinicznym choroby
znajdowa∏o si´ 4 pacjentów, w stadium II – 12, w stadium III – 63, natomiast postaç rozsianà choroby prezentowa∏o 34 dzieci.
AktywnoÊç antygenu Ki-67 oznaczono w utrwalonych w parafinie wycinkach tkanki nowotworowej, uzyskanych w trakcie
pierwotnego zabiegu chirurgicznego, pos∏ugujàc si´ zestawem firmy Dako. Do oceny ekspresji antygenu Ki-67 u˝ywano
mikroskopu Êwietlnego firmy Olympus BX 50 z torem wizyjnym i komputera Pentium 130 z kartà graficznà Frame Grabber
oraz programu komputerowej analizy obrazu Multiscan 5.10. ObecnoÊç antygenu Ki-67 badano w 500 komórkach ka˝dego
preparatu w kilku losowo wybranych polach widzenia, obliczajàc odsetek komórek Ki-67 dodatnich.
W y n i k i.  Âredni indeks proliferacyjny Ki-67 dla ca∏ej grupy wyniós∏ 18,5%. Najwy˝sze Êrednie wartoÊci ekspresji antygenu
Ki–67 stwierdzono w podtypie p´cherzykowym mi´saka prà˝kowanokomórkowego. Wysoka aktywnoÊç proliferacyjna wiàza∏a
si´ z gorszà odpowiedzià guza na chemioterapi´ wst´pnà (p<0,05), a tak˝e z krótszym czasem prze˝ycia wolnego od zdarzeƒ
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Introduction
Soft tissue sarcomas form a heterogenous group of
malignant tumours originating from embryonal mesen-
chymal and neuroectodermal tissue. In Poland they
account about 7% of all childhood malignancies and are
the fifth most common type of tumour (after leukaemias,
tumours of the CNS, lymphomas and neuroblastomas)
diagnosed below 16 years of age [1]. Despite a number of
common biological and clinical features (including the
response to anti-tumour therapy) soft tissue sarcomas
vary histologically, thus causing problems in patient
stratification and in the choice of the best treatment
method. The currently used clinical classification system,
based on the histological type of the tumour, its size and
localization, patient age and the presence of metastases
does not allow for an adequate prediction as to the course
of the disease. Therefore we ought to identify new
prognostic factors, connected to the biological features of
the tumour which would allow to set more precise
treatment strategies individually adapted for each patient
[2]. One such parameter which raises hopes as to an
improvement in the stratification of our young patients is
the grade of malignant cell proliferation, because in
a number of tumours high activity of cell proliferation
correlates with increased malignancy [3, 4].
The level of the activity of cell proliferation may be
assessed through the evaluation of the degree of the Ki-67
antigen expression, the number of nucleoli organizers
and the PCNA (proliferating cell nuclear antigen). The
Ki-67 antigen has been first described in the year 1983 as
a nuclear protein accompanying cell proliferation. It is
encoded on chromosome 10 (10q25) [5]. The full function
of the Ki-67 antigen remains, as for now, unclear. It is
presumed that it may participate in the regulation of
transcryptic activity in the course of cell division. It is
known that Ki-67 expression correlates with DNA
synthesis, but it does not accompany processes of DNA
repair [5]. Recent developments have rendered the
evaluation of Ki-67 much easier – previously fresh tissue
samples had to be frozen, at present it is possible to
evaluate Ki-67 in paraffin-embedded tissue samples with
the aid of MIB1-3 antibodies. This last method has also
allowed to perform such analyses in historical material.
Most literature reports are concerned with Ki-67
antigen expression in soft tissue sarcomas of adult
patients, in whom the high index of proliferation has been
found to correlate with a high grade of malignancy and
poor disease free survival (DFS) [3, 6-12]. The aim of
this study is to examine Ki-67 antigen expression in tissue
samples obtained from children with soft tissue sarcomas
and to evaluate the influence of this parameter on tumour
aggressiveness, its reaction to chemotherapy and on the
outcome of treatment.
Method
I m m u n o h i s t o c h e m i c a l  e v a l u a t i o n  o f  K i - 6 7
a n t i g e n  a c t i v i t y
Ki-67 activity was evaluated in 4 µm thick paraffin-embedded
samples placed on gelatin glass (2g KCr(SO4)2x12H2O + 2.5g
gelatine), and later de-paraffinated in xylene. The samples were
then hydrated in solutions containing decreasing concentrations
of ethyl alcohol and repeatedly rinsed in distilled water. The
hydrated samples were then placed in pH 6.0 citrate buffer and
heated in a microwave oven (95°C for 40 minutes). After cooling
(20 minutes in room temperature) and rinsing twice in TBS
solution the samples were incubated in 3%H2O2 and then rinsed
in distilled water (2 x 5 minutes) and in TBS (2 x 5 minutes).
In order to prove Ki-67 expression we used rabbit serum
against the human Ki-67 antigen (DAKO) in a concentration of
1:50. The samples were incubated with the serum at room
temperature for 45 minutes, with simultaneous control perfor-
med on Ki-67 control slides (DACO, 1073). Excess serum
was rinsed off with TBS (2 x 5 minutes). We used the Bio-
tinylated Goat Antibody to Mouse/Rabbit Immunoglobulins
(StrepABComplex/HRP Duet, Mouse/Rabbit, DAKO K0492) as
the binding (intermediate) antibody, while for the indicator
complex we used the StrepABComplex (StrepABComplex/HRP
Duet, Mouse/Rabbit, DAKO K0492). Both reagents were
incubated at room temperature for 30 minutes and then rinsed
with TBS (2 x 5 minutes).
In order to visualize the reaction we used the DAB
substrate (3,3-diaminobenzidine tetrachlorohydrate – DAKO
DAB Tablets). 6 mg of DAB were dissolved in 0.05 TBS (pH 7.4)
and 0.1 ml of H2O2, and the samples were incubated in this
solution at room temperature for 30 minutes, and then rinsed for
15 minutes. The samples were then stained with Mayer
hematoxylin, rinsed with water, covered with cover glass and
Canada balsam.
In order to perform a quantitative analysis of the Ki-67
positive cells we used an Olympus BX 50 light microscope with
a visual path and a Pentium 130 computer with Frame Grabber
graphic card Multiscan 5.10 software for computerized picture
analysis. We counted all malignant cells (both positive and
negative) discernible within the visual field, and then all ma-
lignant cells showing a positive reaction as to the presence of the
Ki-67 antigen. The presence of Ki-67 was evaluated in 500 cells
of each sample in a few randomly chosen visual fields, and then
the ratio of positive cells was calculated. Only evident brown
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(5-letnie EFS: 0,44 i 0,26; p<0,05) oraz prze˝ycia ca∏kowitego (5-letnie OS: 0,55 i 0,31; p=0,03). Wykazano ponadto, ˝e
w grupie osób z wysokà ekspresjà antygenu Ki-67 istotnie mniejsze sà szanse prze˝ycia po wznowie choroby (p=0,011). Nie
stwierdzono natomiast istotnych zale˝noÊci pomi´dzy indeksem Ki-67 a wielkoÊcià i sposobem rozprzestrzeniania si´ guza,
stadium choroby, zaj´ciem regionalnych w´z∏ów ch∏onnych oraz obecnoÊcià przerzutów.
W n i o s k i.  Na podstawie uzyskanych wyników mo˝na stwierdziç, ˝e ekspresja antygenu Ki-67 jest istotnym czynnikiem
rokowniczym w mi´sakach tkanek mi´kkich u dzieci, a oznaczenie tego parametru pomo˝e uzupe∏niç stratyfikacj´ pacjentów
przed rozpocz´ciem leczenia przeciwnowotworowego i tym samym zwi´kszyç skutecznoÊç stosowanych metod terapeutycznych.
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staining of the cellular nuclei was considered as positive. In
order to perform a control of the immunohistochemical analysis
we performed a simultaneous reaction which repeated the entire
procedure omitting only the incubation with the specific
antibody. Examples of positive reactions are presented in
Figure 1.
Pa t i e n t s
Ki-67 antigen expression had been evaluated in paraffin-
embedded tissue material obtained from 113 children treated by
the Polish Paediatric Solid Tumour Group. Altogether we
analysed the cases of 65 boys (57.5%) and 48 girls (42.5%) aged
between 1 and 217 months (mean age: 105.2 + 65.2 months,
median: 102 months). In 55 cases (48.7%) we recognized the
embryonal form of the rhabdomyosarcoma (RME), in 23 cases
(20.4%) – the alveolar rhabdomyosarcoma (RMA), in 6 cases
(5.3%) – the undifferentiated rhabdomyosarcoma (RMU). In
further 18 cases (15.9%) we diagnosed peripheral primary
neuroectodermal tumours (PNET), in 6 cases (5.3%) – synovial
sarcoma, in 4 cases (3.5%) – extraosseous Ewing sarcoma (EES)
and in 1 case (0.9%) poorly differentiated unclassified sarcoma
(UKS). As to the clinical stage of the disease 4 patients (3.5%)
were in stage I, 12 patients (10.6%) in stage II, 63 patients
(55.8%) in stage III, while in the remaining 34 patients (30.1%)
distant metastases were present at the time of diagnosis.
Regional lymph node involvement (N1 acc. to the TNM
classification) was observed in 26 patients (23%).
In 29 cases (25.7%) the primary tumour was limited to the
organ or tissue of origin (stage T1 acc. to the TNM classifi-
cation), while in 81 patients it infiltrated neighbouring organs
(stage T2). In 3 cases (2.6%) it was impossible to discern the
character of the primary tumour due to the lack of sufficient
data. In 23 cases (20.4%) the diameter of the primary tumour
did not exceed 5 cm, while in 88 cases (77.9%) it was over 5 cm.
In 2 patient the size of the primary tumour was not established.
At the time of analysis (May 2002) 59 patients (52.5%) were
still alive, the 54 remaining patients (47.8%) having died.
S t a t i s t i c a l  a n a l y s i s
Statistical analysis was performed with the aid of the Statis-
tica®97Pl for Windows® software. In order to establish
differences between patient groups we used Student’s T-test (if
parameter distribution was close to normal). In case of non-
parametric values we used the χ2 test, and in groups with less
than 5 subjects – the Fisher’s exact test [13]. The probability of
event-free survival (EFS) was evaluated with the aid of the
Kaplan-Meier method [14] beginning with the day of therapy
onset and ending with the failure day or with the day of the
most recent patient observation. Failure was defined as pro-
gression, recurrence or death (regardless of cause). The
probability of overall survival (OS) was calculated beginning
with day 1 of treatment until the time of death or the day of
the most recent patient observation. Possible differences in the
calculated probability of OS and EFS were verified with the
log-rank test [15], and in case of groups less numerous than 15 –
with Cox’s F test. The confidence level of the analysis was set at
α=0.05, significance level p<0.05.
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Figure 1. Microphotograph of immunohistochemically stained malignant tissue samples examined for the presence of the Ki-67 antigen. A)
embryonal rhabdomyosarcoma (RME) B) alveolar rhabdomyosarcoma (RMA) C) peripheral primary neuroectodermal tumour (PNET) D)
synovial sarcoma (SS)
Results
Due to the lack of a standard value at which Ki-67 antigen
expression could be considered as high for the sake of
this particular study we turned to literature reports and
assumed this level to be set at 20% of cells with Ki-67
antigen expression [6, 7, 12]. Tumours in which at least
20% of cells revealed Ki-67 expression were considered as
those with a high proliferative grade, while tumours in
which Ki-67 expression was found in less than 20% of
cells were considered to possess low proliferative activity.
Ki-67 expression was found in the case of 107
(94.7%) tumours. The mean Ki-67 proliferative index
was 18.5% in the entire group (range: 0%-44.3%); for
the rhabdomyosarcoma group (RMS) – 19.2% (range:
0%-44.3%); for the remaining patients (non-RMS) –
17.9% (range: 0%-40.9%). The highest mean values of
Ki-67 antigen expression were found in the RMA group
(27.4%), and they were significantly higher than in the
RME group (15.5%; p<0.00001). Moreover, in case of
RMA tumours with a higher proliferation grade (>20%
of Ki-67 positive cells) were significantly more common
than in RME (RMA < 20% and >20% – 5 and 18
patients respectively; in RME – 38 and 17 patients
respectively; p<0.001). In the case of RMU the mean
Ki-67 was 21.7%, and for synovial sarcoma – 23.9%. The
lowest expression was observed in EES – reaching 5.6%
and although statistical verification has shown that the
mean values in this group differ significantly as compared
to RMA (p<0.001), RME (p<0.05), PNET (p<0.05)
and SS (p=0.017) groups, yet the very low number of
patients (n = 4) calls for a very careful approach to this
data.
Tumour size, clinical stage, regional lymph node
involvement, the type of tumour spread and the presence
of metastases did not reveal any statistical significant
differences as to the grade of proliferation, both regarding
the mean value of Ki-67 positive cells and regarding the
frequency of tumours with a high proliferative activity.
However, one cannot fail to notice the slightly higher
proliferative activity in more advanced stages of the
disease (stages I-III as compared to stage IV – 17.9%
and 21%, respectively); in the case of primary tumours
over 5 cm in size (<5 cm vs. >5 cm – 16.7% and 19.6%,
respectively); in case of tumours infiltrating neighbouring
organs (T1 vs. T2 – 18.5% and 19.1%, respectively) and in
the case of regional lymph node involvement (N0 vs. N1 –
18.3% and 21.3%, respectively). We have also noticed
that proliferative activity correlates with the reaction of
the tumour to initial chemotherapy. Among the 84
patients in stage III and IV in whom it was possible to
evaluate the response after the first cycle of chemotherapy
we observed complete remission and good response
(tumour regression >2/3 of initial size) more often in
patients with Ki-67 expression <20% (25/47 patients as
compared to 12/37 patients with Ki-67 expression >20%).
On the other hand, tumours with partial response
(regression >1/3 and < 2/3 of initial size) and no response
(<1/3 regression or progression) were more frequent in
the group with the >20% index (Ki-67 expression <20%
and >20% – 22/47 and 25/37, respectively; p<0.05).
Treatment failures were also more common among
patients with high proliferative activity. At the closing of
the analysis in the group with Ki-67 expression <20% 23
patients had died (37.1%), while in the Ki-67 >20%
group there were 31 deaths (60.8%) (p=0.012). It is also
worth noting that among the patients who had died the
mean values of Ki-67 expression were significantly higher,
despite the administration of oncolytics, as compared to
the surviving patients (21.1% vs. 16.8%, respectively;
p=0.04).
EFS and OS of the analysed patients are presented
in Figures 2 and 3. We have shown that patients with
a low proliferative activity (Ki-67 <20%) has a signifi-
cantly higher likelihood of both event free survival (5
year EFS 0.44 and 0.26, respectively; p<0.05) and of
overall survival (5 year OS 0.55 and 0.31, respectively;
p=0.03). We have also shown, that the proliferative
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Figure 2. Event free survival (EFS) in relation to the grade of Ki-67 antigen expression evaluated in tumour cells
activity is also a factor influencing prognosis among
patients with recurrent disease (Figure 4). Patients with
the Ki-67 index of <20% stand a better chance for longer
survival and next disease remission as compared to
patients with the Ki-67 index of >20% (the ratio of
patients still alive after 60 months of follow up from the
time of recurrence being 0.18 vs 0.07, respectively;
p=0.011).
Discussion
The Ki-67 antigen is a commonly recognized marker of
cell proliferation. Literature reports concerning the
activity of Ki-67 in soft tissue sarcomas are few, and they
are mainly devoted to adult patients [6-12]. In those
patients the high proliferative index distinctly correlates
with low EFS, while the level of Ki-67 antigen expression
correlates with the degree of histological malignancy of
the tumour [3, 9, 10]. It has also been shown, that a high
Ki-67 index (>20%) correlates with a higher risk of
developing distant metastases [8, 12]. However, due to
a number of specific characteristics of childhood
sarcomas, as compared to those in adult patients, the
data obtained from adults cannot be directly applied in
the clinical practice concerning patients below 18 years of
age. There is, as for now, no extensive literature report
concerning Ki-67 antigen expression in childhood
sarcomas. We have found only one report on this issue
concerning 25 rhabdomyosarcoma patients, whose
median age was 10.9 years [16]. For that reason we have
attempted to perform an evaluation of this parameter in
the stratification of soft tissue sarcomas of children and
adolescents.
The analysis of our material has shown, that
evaluation of the Ki-67 antigen expression in malignant
cells may be useful for the evaluation of risk factors
among children with soft tissue sarcomas. EFS and OS
were significantly lower in the group of patients with
a high proliferative index, as compared to the group of
patients with a low proliferative index. It is worth noticing,
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Figure 4. Patient survival after relapse in relation to the grade of Ki-67 antigen expression evaluated in tumour cells
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Figure 3. Overall survival (OS) in relation to the grade of Ki-67 antigen expression evaluated in tumour cells
that the proliferative activity of the tumour correlated
not only with the final treatment outcome, but it also
allowed to predict, at least partially, the response of the
tumour to initial chemotherapy. Among patients with
a high Ki-67 index satisfactory tumour regression (>2/3 of
initial size) was significantly less common after the first
cycle of chemotherapy.
An analysis of Ki-67 antigen expression has also
allowed to evaluate the prognosis of patients with
recurrence. A higher proliferative index found in the
material obtained before the onset of treatment corre-
lated with earlier death after recurrence. This finding is all
the more important because in the case of malignancies
with a very high risk of failure the presently-used stra-
tification systems do not allow to identify subjects with
poorer or better prognosis [2,12,17]. In the course of our
study we have not managed to confirm the role of the
Ki-67 antigen in the development of distant metastases. It
may be explained by the fact that the biology of childhood
sarcomas is somewhat different. On the other hand it
cannot be overruled that our group of patient with
metastases was not very numerous (n=34) and therefore
some statistically significant differences may have failed to
appear. Certainly further studies are necessary.
The evaluation of the Ki-67 antigen expression may
also be useful in the histopathological diffrentiation of
soft tissue sarcomas. Basing on our material we may
conclude that the grade of Ki-67 expression correlates
with the histopathological type of the tumour, which may
render histological diagnosis easier.
The role of the Ki-67 antigen in the oncogenesis of
sarcomas remain unclear. Initial reports suggest the
participation of this protein in the complex interactions
occurring during the cellular cycle. It has been observed,
that in cases of Ewing’s sarcoma the level of the Ki-67
antigen correlates with the expression of the c-myc
protooncogene [18]. This oncogene has been found to
amplify in a number of cancers, neuroblastoma-type
tumours and mesenchymal tumours [19]. It has also been
established that a high Ki-67 index accompanies the
nuclear overexpression of the p53 protein, which is
considered to be a sign of mutation within the TP53
suppressor gene [7]. Also, in the case of synovial sarcoma
the high level of Ki-67 expression correlates with the
presence of a specific gene fusion SYT-SSX1 charac-
teristic for this very malignancy [20]. The role of this
mutation in the process of oncogenesis is not yet clear,
however it is suggested that its presence is somehow
related with the significantly worse prognosis of synovial
sarcoma patients [20]. Further studies on the role of the
Ki-67 protein in the cellular cycle and in the process of
oncogenesis are necessary.
To summarise we may state, that Ki-67 activity may
be a useful marker helpful in the process of clinical
examinations designed to assign the patient to a certain
risk group. The analysis of Ki-67 activity is simple to
perform and inexpensive. It may be performed both from
fresh tissue samples and from paraffin-embedded
samples, thus allowing to perform retrospect analyses.
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